Highest-materiality recent filing
OraSure Q2 2026 results announced; no financial details available
Company issued a press release on August 5, 2026, for Q2 2026 results.
OraSure receives FDA clearance for Colli-Pee Dx urine collection kit for STI tests on Roche systems
FDA clearance covers Colli-Pee Dx kit for use with Roche cobas 5800/6800/8800 systems for CT, NG, TV, MG pathogens.
OraSure stockholders approve board declassification and 5M share increase in stock plan
Stockholders approved 5M share increase to Stock Award Plan; total authorized shares now 6,982,477.
OraSure reports Q1 2026 results; specific financial figures not disclosed in filing excerpts
Issued press release with Q1 2026 consolidated financial results.
John D. Bertrand appointed as independent Class II director effective April 16, 2026; term expires at 2026 annual meeting.
Total shareholder return outperformed peer median by ~40% during CEO Carrie Eglinton Manner's tenure (since June 2022).
Director David J. Shulkin resigns from OraSure board effective March 2, 2026
David J. Shulkin, M.D. resigned as director and from Compensation Committee, effective March 2, 2026.
OraSure announces Q4/FY2025 results; exhibit details not provided here
Press release and investor presentation furnished on Feb 25, 2026 for Q4 and full year ended Dec 31, 2025.
OraSure submits two FDA applications for rapid CT/NG self-test and at-home urine collection device
Submitted two FDA 510(k) applications: one for a rapid molecular self-test for Chlamydia and Gonorrhea (CT/NG) and one for the Colli-Pee at-home urine collection device for STI indications.
OraSure CEO and CFO adopt 10b5-1 plans to purchase up to $165K each in common stock
CEO Carrie Eglinton Manner adopted a plan to buy up to $165,000 of OSUR shares over six months.
OraSure Technologies Q3 2025 results announced; financial details not provided in filing exhibits
Company reported Q3 2025 consolidated financial results on November 5, 2025.
OraSure board chair Aspinall resigns; Boyd appointed director, Kenny named chair
Mara G. Aspinall resigned from the board and as chair effective Oct 28, 2025; no dispute cited.
Company issued press release for Q2 2025 consolidated financial results on August 5, 2025.
OraSure shareholders approve amendment to 2000 Stock Award Plan, increasing authorized shares by 6M
Stockholders approved amendment to Stock Award Plan to increase shares authorized for grant by 6,000,000 shares.
Pro forma combined net loss $49.1M, diluted EPS ($0.66) for 2024 after Sherlock acquisition
Acquisition closed Dec 19, 2024; consideration includes $5M upfront, up to $20M milestones, and royalties.
OraSure Chief Product Officer Kathleen Weber resigns, effective June 30, 2025
Kathleen G. Weber notified resignation as Chief Product Officer on May 8, 2025.
OraSure announces Q1 2025 financial results; specific figures not available in filing attachment
Press release dated May 7, 2025 reports Q1 2025 consolidated financial results.
OraSure announces $40M stock repurchase program, terminates 2008 plan
Board authorized up to $40M in common stock repurchases over two years on March 21, 2025.
Sherlock Biosciences posts $34.9M net loss, $149.7M deficit in 9 months before OraSure acquisition
Net loss of $34.9M for nine months ended Sep 30, 2024; $50.9M loss for FY2023.
OraSure reports Q4 2024 financial results: net income $3.2M, EPS $0.26
Q4 2024 net income attributable to OraSure was $3.2 million ($0.26 per share), compared to $0.27 per share in Q4 2023.
Upfront cash payment of $5M plus legal/insurance costs; merger closed December 19, 2024.
OraSure acquires Sherlock Biosciences; deal terms not disclosed in 8-K filing
OraSure announced acquisition of Sherlock Biosciences on December 19, 2024, but no deal value or financial terms provided.
OraSure Technologies reports Q3 2024 results; details not in filing excerpt
Press release and conference call held November 6, 2024 for Q3 2024 results.
OraSure expands board to 7 members, appoints John P. Kenny as independent director
Board increased from 6 to 7 directors; John P. Kenny appointed as Class I director, effective Sept 6.
OraSure reports Q2 2024 earnings; no figures in filing body
Press release issued August 6, 2024, covering Q2 2024 results and business developments.
Stockholders approved amendment to 2000 Stock Award Plan to increase authorized shares by 3,000,000; total now up to 5,302,283 shares.
OraSure announces Q1 2024 results; specific figures not disclosed in filing excerpt
Press release issued May 8, 2024 covering Q1 2024 financial results.
OraSure reports cybersecurity incident with data exfiltration; Q1 revenue guidance reaffirmed
Unauthorized third party gained access to certain information systems on or about March 27, 2024.
OraSure reports Q4/FY2023 results; press release not provided for review
Filed 8-K on Feb 27, 2024 announcing consolidated financial results for Q4 and FY2023.
OraSure invests in KKR Sapphiros, enters wide-ranging distribution deal
OraSure announces investment in KKR Sapphiros, L.P. and a multi-faceted distribution relationship.
OraSure replaces KPMG with Grant Thornton as auditor; discloses material weakness
KPMG dismissed after 2023 audit completion; Grant Thornton appointed for FY2024, effective upon dismissal.
OraSure announces Q3 2023 results; specific figures not provided in filing excerpt
Press released November 7, 2023, covering Q3 2023 consolidated financial results and business updates.
OraSure Q2 2023 earnings announced but no financial details in filing text provided
Press release dated August 3, 2023, issued but not included in the submitted text.
OraSure board sets annual say-on-pay votes through 2029 after shareholder advisory vote
Board determined on Aug 1, 2023 to hold annual say-on-pay votes after 55.8M shares (93.7%) favored one-year frequency.
OraSure expands board to seven, appoints Robert W. McMahon as Class II director
Board size increased from 6 to 7, effective July 31, 2023.
OraSure shareholders approve 3M share increase to Stock Award Plan; annual meeting results
Shareholders approved amended 2000 Stock Award Plan, adding 3,000,000 authorized shares.
OraSure amends bylaws to align with SEC universal proxy rules
Bylaws amended effective May 9, 2023 to incorporate SEC universal proxy rule requirements.
OraSure Q1 record revenue $155M, GAAP EPS $0.37; guides Q2 rev $62-67M
Total net revenue $155.0M (+129% YoY); InteliSwab revenue $118.3M (+33% sequential).
OraSure SVP of Corporate Communications and IR Scott Gleason resigns effective May 26, 2023
Scott Gleason notified resignation on March 15, 2023; effective May 26, 2023.
OraSure Q4 revenue record $123.1M (+94% YoY); GAAP EPS $0.21; restructuring cuts 11% of workforce
Q4 revenue $123.1M record (+94% YoY); InteliSwab $88.9M (+502% YoY, +12% sequential).
Contract from US Defense Logistics Agency for InteliSwab COVID-19 Rapid Test; runs Nov 2022 to Nov 2023.
Kathleen G. Weber, previously President of Molecular Solutions, appointed as Chief Product Officer effective Nov 14, 2022.
OraSure posts record Q3 revenue of $116.5M, up 116% YoY; InteliSwab drives growth
GAAP net income $5.3M ($0.07 diluted EPS) vs. loss of $15.0M a year ago; non-GAAP EPS $0.13.
OraSure appoints Ken McGrath as CFO; three directors resign as part of strategic transformation
Ken McGrath named CFO effective Aug 8, 2022; succeeds Scott Gleason, who served as interim CFO since Sep 2021.
OraSure Q2 revenue record $80.2M (+39% YoY) but GAAP EPS ($0.26); InteliSwab sales surge 95% QoQ
GAAP net loss of $18.8M vs. $1.4M loss in Q2 2021; gross margin fell to 34.4% from 53.2%.
OraSure President of Molecular Solutions rescinds resignation; board accepts retention
Kathleen G. Weber rescinded her May 23 resignation as President of Molecular Solutions.
OraSure General Counsel and CCO to depart June 25 after citing organizational changes
Agnieszka M. Gallagher, EVP, General Counsel and Chief Compliance Officer, notified termination with Good Reason on June 3, 2022.
OraSure appoints Carrie Eglinton Manner CEO effective June 4; ends strategic alternatives review
Carrie Eglinton Manner appointed President and CEO, effective June 4, 2022; replaces interim CEO Nancy Gagliano.
OraSure shareholders approve 1.5M share increase in stock award plan; reelect directors
Stockholders approved amended stock award plan, increasing authorized shares by 1,500,000 to 3,621,685.
OraSure Q1 record revenue $67.7M (+16% YoY) but net loss $20M, InteliSwab scales
Net loss of $20.0M ($0.28 diluted EPS) vs net income of $3.8M ($0.05) in Q1 2021; operating loss $16.0M.
On May 8, 2025, Kathleen G. Weber notified OraSure Technologies, Inc. (the “Company”) of her resignation as Chief Product Officer of the Company, effective June 30, 2025.
the Board appointed John P. Kenny as a new member of the Board, with such appointment to be effective as of the Effective Date.
the Board appointed Robert W. McMahon as a new member of the Board, with such appointment to be effective as of the Effective Date.
On March 15, 2023, Scott Gleason, who currently serves as the Company’s Senior Vice President of Corporate Communications and Investor Relations, notified the Company of his resignation from the Company, effective May 26, 2023, in order to pursue another opportunity.
On November 7, 2022, the board of directors of OraSure Technologies, Inc. (the “Company”) appointed Kathleen G. Weber, the Company’s current President of Molecular Solutions, as the Company’s Chief Product Officer, effective November 14, 2022.
Mr. McGrath will succeed Mr. Scott Gleason, who has served as the Company’s Interim Chief Financial Officer since September 2021.
On August 8, 2022, the board of directors (the “Board”) of OraSure Technologies, Inc. (the “Company”) appointed Ken McGrath as the Company’s Chief Financial Officer, effective August 8, 2022 (the “Effective Date”).
Ms. Weber has notified the Company of her decision to rescind her resignation as President of Molecular Solutions.
On June 3, 2022, Agnieszka M. Gallagher, who currently serves as OraSure Technologies, Inc.’s (the “Company”) Executive Vice President, General Counsel and Chief Compliance Officer, notified the Company of her termination of her employment with the Company with Good Reason (as defined in her employment agreement, dated as of November 29, 2021) related to Company organizational changes.
Ms. Eglinton Manner will be appointed by the Board to serve as a Class I director on the Board as of the Effective Date.
the board of directors (the “Board”) of the Company will appoint Ms. Eglinton Manner as the Company’s President and Chief Executive Officer, effective June 4, 2022
Dr. Gagliano will resign, effective June 4, 2022, from her position as the Company’s interim Chief Executive Officer.
Max materiality 0.78 · Median 0.50 · Most common event earnings